Literature DB >> 12891553

Pathogenicity of the hereditary colorectal cancer mutation hMLH1 del616 linked to shortage of the functional protein.

Tiina E Raevaara1, Carlos Vaccaro, Wael M Abdel-Rahman, Esteban Mocetti, Shashi Bala, Karin E Lönnqvist, Reetta Kariola, Henry T Lynch, Päivi Peltomäki, Minna Nyström-Lahti.   

Abstract

BACKGROUND & AIMS: Hereditary nonpolyposis colorectal cancer is associated with mismatch repair deficiency. Most predisposing mutations prevent the production of functional mismatch repair protein. Thus, when the wild-type copy is also inactivated, the cell becomes mismatch repair deficient, and this leads to a high degree of microsatellite instability in tumors. However, tumors linked to nontruncating mutations may display positive or partly positive immunohistochemical staining of the mutated protein and low or atypical microsatellite instability status, which suggests impaired functional activity but not a total lack of mismatch repair. We found human mutL homology (hMLH) 1 del616, one of the most widespread recurring mutations in hereditary nonpolyposis colorectal cancer, segregating in a large hereditary nonpolyposis colorectal cancer family. Because the predicted coding change is a deletion of only 1 amino acid, the pathogenicity of the mutation was evaluated.
METHODS: Many analyses were performed to assess the pathogenicity of hMLH1 del616 and to study the expression and function of the mutated messenger RNA and protein.
RESULTS: Genetic and immunohistochemical evidence supported hMLH1-linked cancer predisposition in this family. Microsatellite instability varied from low to high, and the hMLH1 protein was lost in 2 tumors but was partly detectable in 1 tumor. Whereas similar optimal amounts of mutated hMLH1 del616 and wild-type hMLH1 proteins were equally functional in an in vitro mismatch repair assay, the amount of in vivo-expressed hMLH1 del616 was much lower than the amount of wild-type protein; this suggests that the deletion imparts instability to the mutant protein.
CONCLUSIONS: Our results suggest that the pathogenicity of hMLH1 del616 is not linked to nonfunctionality, but to shortage of the functional protein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12891553     DOI: 10.1016/s0016-5085(03)00905-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Functional characterization of rare missense mutations in MLH1 and MSH2 identified in Danish colorectal cancer patients.

Authors:  Lise Lotte Christensen; Reetta Kariola; Mari K Korhonen; Friedrik P Wikman; Lone Sunde; Anne-Marie Gerdes; Henrik Okkels; Carsten A Brandt; Inge Bernstein; Thomas V O Hansen; Rikke Hagemann-Madsen; Claus L Andersen; Minna Nyström; Torben F Ørntoft
Journal:  Fam Cancer       Date:  2009-08-21       Impact factor: 2.375

2.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer.

Authors:  Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Mark Clendenning; Kaisa Sotamaa; Thomas Prior; Judith A Westman; Jenny Panescu; Dan Fix; Janet Lockman; Jennifer LaJeunesse; Ilene Comeras; Albert de la Chapelle
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

Review 3.  Application of molecular diagnostics for the detection of Lynch syndrome.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Expert Rev Mol Diagn       Date:  2010-07       Impact factor: 5.225

Review 4.  Lynch syndrome genes.

Authors:  Päivi Peltomäki
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas.

Authors:  Maria Simona Pino; Mari Mino-Kenudson; Bernadette Mandes Wildemore; Aniruddha Ganguly; Julie Batten; Isabella Sperduti; Anthony John Iafrate; Daniel C Chung
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

6.  Lynch syndrome in South America: past, present and future.

Authors:  Carlos A Vaccaro; Carlos Sarroca; Benedito Rossi; Francisco Lopez-Kostner; Mev Dominguez; Natalia Causada Calo; Raul Cutait; Adriana Della Valle; Lina Nuñez; Florencia Neffa; Karin Alvarez; Maria Laura Gonzalez; Pablo Kalfayan; Henry T Lynch; James Church
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

7.  Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs found in cancer patients.

Authors:  Jukka Kantelinen; Minttu Kansikas; Satu Candelin; Heather Hampel; Betsy Smith; Liisa Holm; Reetta Kariola; Minna Nyström
Journal:  Hum Mutat       Date:  2012-06-11       Impact factor: 4.878

8.  Verification of the three-step model in assessing the pathogenicity of mismatch repair gene variants.

Authors:  Minttu Kansikas; Reetta Kariola; Minna Nyström
Journal:  Hum Mutat       Date:  2011-01       Impact factor: 4.878

9.  C-terminal fluorescent labeling impairs functionality of DNA mismatch repair proteins.

Authors:  Angela Brieger; Guido Plotz; Inga Hinrichsen; Sandra Passmann; Ronja Adam; Stefan Zeuzem
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

10.  MSH6 missense mutations are often associated with no or low cancer susceptibility.

Authors:  R Kariola; H Hampel; W L Frankel; T E Raevaara; A de la Chapelle; M Nyström-Lahti
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.